UNDERWRITING AGREEMENT between ALTAMIRA THERAPEUTICS LTD. and THINKEQUITY LLC as Representative of the Several Underwriters ALTAMIRA THERAPEUTICS LTD.Underwriting Agreement • March 23rd, 2023 • Altamira Therapeutics Ltd. • Pharmaceutical preparations • New York
The undersigned, Altamira Therapeutics Ltd., an exempted company limited by shares incorporated in Bermuda (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of Altamira Therapeutics Ltd., the “Company”), hereby confirms its agreement (this “Agreement”) with ThinkEquity LLC (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
WARRANT AGENT AGREEMENTWarrant Agent Agreement • March 23rd, 2023 • Altamira Therapeutics Ltd. • Pharmaceutical preparations • New York
Amendment No. 3 to Convertible Loan AgreementConvertible Loan Agreement • March 23rd, 2023 • Altamira Therapeutics Ltd. • Pharmaceutical preparations
Reference is made to the Convertible Loan Agreement dated February 4, 2022, as amended on January 26, 2023 and March 9, 2023 (the “Agreement”), between FiveT Investment Management Ltd. (the “Lender”) and Altamira Therapeutics Ltd. (the “AMTL”). The parties hereby agree that, effective as of the date hereof, the Agreement shall be amended as follows:
